Crossmark

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?

Published Online: 2021-03-27

Published Print: 2021-11

Authors

Lebacle, Cedric

Loriot, Yohann

Irani, Jacques https://orcid.org/0000-0002-6321-9144
License Information

Text and Data Mining valid from 2021-03-27

Version of Record valid from 2021-03-27
More Information

Article History

Received: 26 October 2020

Accepted: 10 March 2021

First Online: 27 March 2021

Compliance with ethical standards

:

: Jacques Irani: Investigator in study NCT03519256 (evaluating Nivolumab +—BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib); Cédric Lebacle: Investigator in study NCT03519256 (evaluating Nivolumab +—BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib); Yohann Loriot: Investigator in study NCT03519256 (evaluating Nivolumab +—BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib).

Document is current